高リン血症治療薬の北米市場

Inkwood Researchが発行した調査報告書(INKW709081)
◆英語タイトル:North America Hyperphosphatemia Drug Market Forecast 2017-2025
◆商品コード:INKW709081
◆発行会社(リサーチ会社):Inkwood Research
◆発行日:2017年6月24日
◆ページ数:71
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:北米
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD1,250 ⇒換算¥141,250見積依頼/購入/質問フォーム
Multi LicenseUSD1,500 ⇒換算¥169,500見積依頼/購入/質問フォーム
Enterprisewide Price (Global Site License)USD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はInkwood Research社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Inkwood Research社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

KEY FINDINGSThe North America hyperphosphatemia drug market is expected to grow at a CAGR of 14.76%. The region is expected to hold the largest share in the market with an anticipated increase in the revenue from $721 million in 2017 to $2470 million by 2025. Diabetes and hypertension are the main causes of renal failure, which in turn leads to hyperphosphatemia. Increasing prevalence of these chronic diseases along with unattended medical needs are driving the hyperphosphatemia drug market in this region.

MARKET INSIGHTS
The changing dietary patterns along with the increasing cases of osteoporosis diseases in countries like the United States and Canada are providing the hyperphosphatemia drug market with plenty of growth opportunities. The market is mainly categorized by the different types of drug binders such as iron-based phosphate binders, magnesium-based phosphate binders, aluminum-based phosphate binders, calcium-based phosphate binders and others. The aluminum-based phosphate binders generated a revenue of $203 million in 2016 and are widely used with magnesium-based phosphate binders for treating patients on dialysis. However, it is the calcium-based phosphate binders that held the largest market share of 54.75% in 2016 and are expected to continue their dominance throughout the forecasted period. Despite such phenomenal growth, the market is facing some tough challenges due to the various limitations imposed by the Food and Drug Administration (FDA) and the rising side effects observed due to the use of some of the hyperphosphatemia drugs.

COMPETITIVE INSIGHTS
Some of the eminent companies in the hyperphosphatemia drug market include Royal Dsm, Amag, Sun Pharma, and Keryx. Other top players in the market are Zeria Pharmaceutical, Johnson and Johnson, Bruno Pharmaceutical Spa, Cipla, Ultragenyx, Fresenius Medical Care, Roche Diagnostics Corporation, R.H. Moore Drug Co, Sanofi, Fermenta Biotech Ltd Vifor Pharma, Shire, and Pfizer Inc

【レポートの目次】

1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
2.5. ESTIMATION METHODOLOGY
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
4. MARKET DETERMINANTS
4.1. DRIVERS
4.1.1. GROWING PREVALENCE OF CHRONIC DISEASES
4.1.2. UNMET MEDICAL NEEDS
4.1.3. HIGH PROPORTION OF ELDERLY PEOPLE
4.1.4. RISE IN PUBLIC AWARENESS
4.2. RESTRAINTS
4.2.1. LIMITATIONS LEVIED BY THE FOOD AND DRUG ADMINISTRATION(FDA)
4.2.2. GROWING SIDE EFFECTS OF THE HYPERPHOSPHATEMIA DRUGS
4.3. OPPORTUNITIES
4.3.1. ASIA PACIFIC REGIONS ARE EXPECTED TO PROPEL THE MARKET GROWTH
4.4. CHALLENGES
4.4.1. NON-ADHERENCE TO TREATMENT REGIMENS
4.4.2. SIDE EFFECTS OF DRUGS
4.4.3. LIMITED AVAILABILITY OF DRUGS
4.4.4. USE OF ADVANCED DIALYSIS TECHNIQUES
5. MARKET SEGMENTATION
5.1. MARKET BY FORMULATION
5.1.1. CALCIUM-BASED PHOSPHATE BINDERS
5.1.2. ALUMINUM-BASED PHOSPHATE BINDERS
5.1.3. MAGNESIUM-BASED PHOSPHATE BINDERS
5.1.4. IRON-BASED PHOSPHATE BINDERS
5.1.5. OTHER PHOSPHATE BINDERS
6. KEY ANALYTICS
6.1. PORTER’S FIVE FORCE MODEL
6.1.1. THREAT OF NEW ENTRANTS
6.1.2. BARGAINING POWER OF BUYERS
6.1.3. BARGAINING POWER OF SUPPLIERS
6.1.4. THREAT OF SUBSTITUTE PRODUCT
6.1.5. INTENSITY OF COMPETITIVE RIVALRY
6.2. OPPORTUNITY MATRIX
6.3. KEY BUYING CRITERIA
6.3.1. APPLICATION
6.3.2. PRICING
6.3.3. EFFECTIVENESS
6.3.4. AVAILABILITY
6.4. STRATEGIC RECOMMENDATION & STRATEGIC CONCLUSIONS
7. GEOGRAPHIC ANALYSIS
7.1. NORTH AMERICA
7.1.1. UNITED STATES
7.1.2. CANADA
8. COMPETITIVE LANDSCAPE
8.1. MARKET SHARE ANALYSIS
8.2. TOP WINNING STRATEGIES
8.2.1. CASE STUDIES: TOP COMPETITIVE MOVES
9. COMPANY PROFILE
9.1. AMAG PHARMACEUTICALS
9.1.1. OVERVIEW
9.1.2. PRODUCT PORTFOLIO
9.1.3. SCOT ANALYSIS
9.1.4. STRATEGIC ANALYSIS
9.2. JOHNSON AND JOHNSON
9.2.1. COMPANY OVERVIEW
9.2.2. SCOT ANALYSIS
9.2.3. STRATEGIC ANALYSIS
9.3. CIPLA
9.3.1. OVERVIEW
9.3.2. PRODUCT PORTFOLIO
9.3.3. SCOT ANALYSIS
9.3.4. STRATEGIC ANALYSIS
9.4. KERYX BIOPHARMACEUTICALS
9.4.1. OVERVIEW
9.4.2. STRATEGIC INITIATIVES
9.4.3. SCOT ANALYSIS
9.4.4. STRATEGIC ANALYSIS
9.5. DSM
9.5.1. OVERVIEW
9.5.2. PRODUCT PORTFOLIO
9.5.3. SCOT ANALYSIS
9.6. BIOTECH PHARMACAL
9.6.1. OVERVIEW
9.6.2. STRATEGIC INITIATIVES
9.6.3. PRODUCTS PORTFOLIO
9.6.4. SCOT ANALYSIS
9.7. SUN PHARM INC
9.7.1. OVERVIEW
9.7.2. STRATEGIC INITIATIVE
9.7.3. SCOT ANALYSIS
9.7.4. STRATEGIC ANALYSIS
9.8. ZERIA PHARMACEUTICAL
9.8.1. OVERVIEW
9.8.2. PRODUCT PORTFOLIO
9.8.3. SCOT ANALYSIS
9.8.4. STRATEGIC ANALYSIS
9.9. ULTRAGENYX
9.9.1. OVERVIEW
9.9.2. SCOT ANALYSIS
9.9.3. STRATEGIC ANALYSIS
9.10. BRUNO FARMACEUTICI SPA
9.10.1. OVERVIEW
9.10.2. PRODUCT PORTFOLIO
9.10.3. STRATEGIC INITIATIVES
9.10.4. SCOT ANALYSIS
9.11. FERMENTA BIOTECH LTD
9.11.1. OVERVIEW
9.11.2. PRODUCT PORTFOLIO
9.11.3. SCOT ANALYSIS
9.11.4.
9.11.5. STRATEGIC ANALYSIS
9.12. PFIZER INC.
9.12.1. OVERVIEW
9.12.2. PRODUCT PORTFOLIO
9.13. ROCHE DIAGNOSTICS CORPORATION
9.13.1. OVERVIEW
9.13.2. STRATEGIC INITIATIVES
9.13.3. SCOT ANALYSIS
9.13.4. PRODUCT PORTFOLIO
9.13.5. STRATEGIC ANALYSIS
9.14. R.H. MOORE DRUG CO.
9.14.1. OVERVIEW
9.14.2. PRODUCT PORTFOLIO
9.14.3. SCOT
9.14.4. STRATEGIC ANALYSIS
9.15. VIFOR PHARMA
9.15.1. OVERVIEW
9.15.2. PRODUCT PORTFOLIO
9.15.3. SCOT
9.15.4. STRATEGIC ANALYSIS
9.16. SANOFI
9.16.1. OVERVIEW
9.16.2. PRODUCT PORTFOLIO
9.16.3. SCOT ANALYSIS
9.16.4. STRATEGIC ANALYSIS
9.17. SHIRE
9.17.1. OVERVIEW
9.17.2. PRODUCT PORTFOLIO
9.17.3. SCOT ANALYSIS
9.17.4. STRATEGIC ANALYSIS
9.18. FRESENIUS MEDICAL CARE
9.18.1. OVERVIEW
9.18.2. PRODUCT PORTFOLIO
9.18.3. SCOT ANALYSIS
9.18.4. STRATEGIC ANALYSIS

TABLE LIST
TABLE # 1 NORTH AMERICA HYPERPHOSPHATEMIA DRUG MARKET BY FORMULATION 2017-2025($ MILLION)
TABLE # 2 IRON-BASED HYPERPHOSPHATEMIA DRUG APPROVAL STATUS 2014-2017
TABLE # 1 WORLDWIDE PREVALENCE OF DIABETES 2015 AND 2035 (MILLIONS)
TABLE # 2 WORLDWIDE POPULATION AGED 80 AND ABOVE 1950-2050 (MILLIONS)
TABLE # 3 PHOSPHOROUS LEVELS IN SELECT FOODS
TABLE # 4 NORTH AMERICA HYPERPHOSPHATEMIA DRUGS MARKET BY FORMULATION 2017-2025($ MILLION)
TABLE # 5 NORTH AMERICA HYPERPHOSPHATEMIA DRUGS MARKET BY CALCIUM-BASED PHOSPHATE BINDERS 2017-2025($ MILLION)
TABLE # 6 NORTH AMERICA HYPERPHOSPHATEMIA DRUGS MARKET BY ALUMINUM-BASED PHOSPHATE BINDERS 2017-2025($ MILLION)
TABLE # 7 NORTH AMERICA HYPERPHOSPHATEMIA DRUGS MARKET BY MAGNESIUM-BASED PHOSPHATE BINDERS 2017-2025($ MILLION)
TABLE # 8 NORTH AMERICA HYPERPHOSPHATEMIA DRUGS MARKET BY IRON-BASED PHOSPHATE BINDERS 2017-2025($ MILLION)
TABLE # 9 NORTH AMERICA HYPERPHOSPHATEMIA DRUGS MARKET BY OTHER PHOSPHATE BINDERS 2017-2025($ MILLION)
TABLE # 10 NORTH AMERICA HYPERPHOSPHATEMIA DRUGS MARKET 2017-2025($ MILLION)

FIGURE LIST
FIGURE # 1 RATE OF ADHERENCE TO PHOSPHATE BINDERS
FIGURE # 2 DIAGNOSIS AND CLINICAL INDICATORS OF CHRONIC KIDNEY DISEASE
FIGURE # 3 NORTH AMERICA HYPERPHOSPHATEMIA DRUGS MARKET BY CALCIUM-BASED PHOSPHATE BINDERS 2017-2025($ MILLION)
FIGURE # 4 NORTH AMERICA HYPERPHOSPHATEMIA DRUGS MARKET BY ALUMINUM-BASED PHOSPHATE BINDERS 2017-2025($ MILLION)
FIGURE # 5 NORTH AMERICA HYPERPHOSPHATEMIA DRUGS MARKET BY MAGNESIUM-BASED PHOSPHATE BINDERS 2017-2025($ MILLION)
FIGURE # 6 NORTH AMERICA HYPERPHOSPHATEMIA DRUGS MARKET BY IRON-BASED PHOSPHATE BINDERS 2017-2025($ MILLION)
FIGURE # 7 NORTH AMERICA HYPERPHOSPHATEMIA DRUGS MARKET BY OTHER PHOSPHATE BINDERS 2017-2025($ MILLION)
FIGURE # 8 PORTERS 5 FORCE MODEL OF HYPERPHOSPHATEMIA MARKET
FIGURE #9 MARKET SHARE OF ANALYSIS OF KEY PLAYERS 2016 (%)
FIGURE # 10 UNITED STATES HYPERPHOSPHATEMIA DRUGS MARKET 2017-2025($ MILLION)
FIGURE # 11 CANADA HYPERPHOSPHATEMIA DRUGS MARKET 2017-2025($ MILLION)



【レポートのキーワード】

高リン血症治療薬

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 高リン血症治療薬の北米市場(North America Hyperphosphatemia Drug Market Forecast 2017-2025)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆